ICP-248 Clinical Trials
5 recruitingDrug
Phase 13Phase 22Phase 31
Showing 1–5 of 5 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 1
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 1
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.191 enrolled22 locationsNCT05728658
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Mature B-cell Malignancies
InnoCare Pharma Inc.78 enrolled8 locationsNCT06351527